<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03713684</url>
  </required_header>
  <id_info>
    <org_study_id>EFC14893</org_study_id>
    <secondary_id>U1111-1189-5009</secondary_id>
    <nct_id>NCT03713684</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)</brief_title>
  <acronym>AMPLITUDE-L</acronym>
  <official_title>A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to&#xD;
      placebo in glycated hemoglobin (HbA1c) change in participants with type 2 diabetes mellitus&#xD;
      (T2DM) inadequately controlled with basal insulin alone or in combination with oral&#xD;
      antidiabetic drugs (OADs).&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To demonstrate the superiority of once weekly injection of efpeglenatide in comparison&#xD;
           to placebo on glycemic control.&#xD;
&#xD;
        -  To demonstrate the superiority of once weekly injection of efpeglenatide in comparison&#xD;
           to placebo on body weight.&#xD;
&#xD;
        -  To evaluate the safety of once weekly injection of efpeglenatide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study duration per participant is approximately 64 weeks including an up to 2-week Screening&#xD;
      Period, a 30-week Core Treatment Period, a 26-week Safety Extension Period, and a 6-week&#xD;
      safety Follow-up Period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision to cancel TRIAL, not related to safety concern&#xD;
  </why_stopped>
  <start_date type="Actual">November 9, 2018</start_date>
  <completion_date type="Actual">January 4, 2021</completion_date>
  <primary_completion_date type="Actual">November 20, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in glycated hemoglobin (HbA1c)</measure>
    <time_frame>Baseline to Week 30</time_frame>
    <description>Change from Baseline to Week 30 in HbA1c</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Baseline to Week 56</time_frame>
    <description>Change from Baseline to Week 56 in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose (FPG)</measure>
    <time_frame>Baseline to Week 30</time_frame>
    <description>Change from Baseline to Week 30 in FPG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with HbA1c &lt;7.0%</measure>
    <time_frame>Baseline to Week 30</time_frame>
    <description>Number of participants with HbA1c &lt; 7.0% at Week 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Baseline to Week 30 and Week 56</time_frame>
    <description>Change from Baseline to Week 30 and Week 56 in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic participants</measure>
    <time_frame>Baseline to Week 56</time_frame>
    <description>Number of participants with at least one hypoglycemic event during treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic events</measure>
    <time_frame>Baseline to Week 56</time_frame>
    <description>Number of hypoglycemic events per participant-year during treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Baseline to Week 30 and Week 56</time_frame>
    <description>Number of participants with AEs</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">370</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Efpeglenatide low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Efpeglenatide low dose (prefilled syringe) administered once weekly for 56 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efpeglenatide middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Efpeglenatide middle dose (prefilled syringe) administered once weekly for 56 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efpeglenatide high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Efpeglenatide high dose (prefilled syringe) administered once weekly for 56 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo (prefilled syringe) administered once weekly for 56 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efpeglenatide SAR439977</intervention_name>
    <description>Pharmaceutical form: solution for injection Route of administration: subcutaneous</description>
    <arm_group_label>Efpeglenatide high dose</arm_group_label>
    <arm_group_label>Efpeglenatide low dose</arm_group_label>
    <arm_group_label>Efpeglenatide middle dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: solution for injection Route of administration: subcutaneous</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine</intervention_name>
    <description>Pharmaceutical form: solution for injection Route of administration: subcutaneous</description>
    <arm_group_label>Efpeglenatide high dose</arm_group_label>
    <arm_group_label>Efpeglenatide low dose</arm_group_label>
    <arm_group_label>Efpeglenatide middle dose</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Participant must be ≥18 years of age at the time of signing the informed consent.&#xD;
&#xD;
          -  Participants with type 2 diabetes mellitus (T2DM).&#xD;
&#xD;
          -  Diabetes diagnosed at least 1 year before screening.&#xD;
&#xD;
          -  Participants on basal insulin regimen alone or in combination with oral antidiabetic&#xD;
             drugs (OADs) for at least 6 months prior to screening.&#xD;
&#xD;
          -  Glycated hemoglobin (HbA1c) between 7.0% and 10.0% (inclusive) measured by the central&#xD;
             laboratory at screening.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History of severe hypoglycemia requiring emergency room admission or hospitalization&#xD;
             within 3 months prior to screening.&#xD;
&#xD;
          -  Retinopathy or maculopathy with one of the following treatments, either recent (within&#xD;
             3 months prior to screening) or planned: intravitreal injections or laser or&#xD;
             vitrectomy surgery.&#xD;
&#xD;
          -  Clinically relevant history of gastrointestinal disease associated with prolonged&#xD;
             nausea and vomiting, including (but not limited to) gastroparesis, unstable and not&#xD;
             controlled gastroesophageal reflux disease requiring medical treatment within 6 months&#xD;
             prior to screening.&#xD;
&#xD;
          -  History of pancreatitis (unless pancreatitis was related to gallstones and&#xD;
             cholecystectomy has been performed), pancreatitis during previous treatment with&#xD;
             incretin therapies, chronic pancreatitis, pancreatectomy.&#xD;
&#xD;
          -  Personal or family history of medullary thyroid cancer (MTC) or genetic conditions&#xD;
             that predispose to MTC (e.g., multiple endocrine neoplasia syndromes).&#xD;
&#xD;
          -  Body weight change of ≥5 kg within the last 3 months prior to screening.&#xD;
&#xD;
          -  Systolic blood pressure &gt;180 mmHg and/or diastolic blood pressure &gt;100 mmHg at&#xD;
             randomization.&#xD;
&#xD;
          -  End-stage renal disease as defined by estimated glomerular filtration rate (eGFR, by&#xD;
             Modification of Diet in Renal Disease [MDRD]) of &lt;15 mL/min/1.73 m2.&#xD;
&#xD;
          -  Laboratory findings at the screening Visit:&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;3 x upper&#xD;
                  limit of normal (ULN) or total bilirubin &gt;1.5 x ULN (except in case of documented&#xD;
                  Gilbert's syndrome);&#xD;
&#xD;
               -  Amylase and/or lipase: &gt;3 x ULN;&#xD;
&#xD;
               -  Calcitonin ≥5.9 pmol/L (20 pg/mL).&#xD;
&#xD;
          -  Gastric surgery or other gastric procedures intended for weight loss within 2 years&#xD;
             prior to screening, or planned during study period.&#xD;
&#xD;
          -  Pregnant (confirmed by serum pregnancy test at screening) or breast-feeding women.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) not willing to use highly effective method(s)&#xD;
             of birth control or who are unwilling to be tested for pregnancy during the study&#xD;
             period and for at least 5 weeks after the last dose of study intervention.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 8400038</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400035</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400005</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400058</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400009</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400057</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400045</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400040</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400026</name>
      <address>
        <city>Van Nuys</city>
        <state>California</state>
        <zip>91405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400055</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400041</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400025</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400052</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400044</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400001</name>
      <address>
        <city>Bridgeton</city>
        <state>New Jersey</state>
        <zip>08302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400039</name>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400036</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400013</name>
      <address>
        <city>Maumee</city>
        <state>Ohio</state>
        <zip>43537</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400030</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400063</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400043</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400037</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560005</name>
      <address>
        <city>Baotou</city>
        <zip>014010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560017</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560006</name>
      <address>
        <city>Changsha</city>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560001</name>
      <address>
        <city>China</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560036</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560012</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560013</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560004</name>
      <address>
        <city>Shanghai</city>
        <zip>200065</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560003</name>
      <address>
        <city>Zhengzhou Shi</city>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100009</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100001</name>
      <address>
        <city>Daejeon</city>
        <zip>35233</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100010</name>
      <address>
        <city>Gwangju</city>
        <zip>61453</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100016</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100015</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100014</name>
      <address>
        <city>Jeonju-Si</city>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100003</name>
      <address>
        <city>Korea</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100005</name>
      <address>
        <city>Korea</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100006</name>
      <address>
        <city>Korea</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100008</name>
      <address>
        <city>Korea</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100007</name>
      <address>
        <city>Seongnam-Si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100002</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100011</name>
      <address>
        <city>Seoul</city>
        <zip>07345</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100004</name>
      <address>
        <city>Seoul</city>
        <zip>3722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100012</name>
      <address>
        <city>Suwon,</city>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100013</name>
      <address>
        <city>Uijeongbu-Si</city>
        <zip>11765</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 18, 2018</study_first_submitted>
  <study_first_submitted_qc>October 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2018</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Efpeglenatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>November 4, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

